News & Updates

Early noninferior to delayed NOAC initiation after stroke in AF patients
Early noninferior to delayed NOAC initiation after stroke in AF patients
13 Oct 2022

Early initiation of nonvitamin K antagonist oral anticoagulants (NOACs) after acute ischaemic stroke in patients with atrial fibrillation (AF) appears to yield similar outcomes when compared with delayed initiation, as shown in the results of the TIMING* study.

Early noninferior to delayed NOAC initiation after stroke in AF patients
13 Oct 2022
Safinamide for Parkinson’s: Dyskinesia up short term, motor symptoms down long term
Safinamide for Parkinson’s: Dyskinesia up short term, motor symptoms down long term
12 Oct 2022 byNatalia Reoutova

A post-hoc analysis of a phase III trial of long-term safinamide for Parkinson’s disease (PD) finds a significant early increase in pre-existing dyskinesia as well as improved motor symptoms in patients with or without pre-existing dyskinesia at 1 year.

Safinamide for Parkinson’s: Dyskinesia up short term, motor symptoms down long term
12 Oct 2022
Dimethyl fumarate bests interferon β-1a in paediatric-onset multiple sclerosis
Dimethyl fumarate bests interferon β-1a in paediatric-onset multiple sclerosis
10 Oct 2022

The use of dimethyl fumarate (DMF) in the treatment of children with paediatric-onset multiple sclerosis (POMS) appears to produce more favourable effects than interferon β-1a (IFNβ-1a), with those on DMF being less likely to have new or newly enlarging lesions and experience relapse, according to data from the open-label CONNECT study.

Dimethyl fumarate bests interferon β-1a in paediatric-onset multiple sclerosis
10 Oct 2022
Acupuncture eases anxiety in patients with Parkinson’s disease
Acupuncture eases anxiety in patients with Parkinson’s disease
03 Oct 2022